ZSCAN18 and breast cancer: Based on the best cutoff value, analysis of 1,879 BC patients using the Kaplan–Meier plotter demonstrated that high mRNA expression of ZSCAN18 was significantly associated with improved OS (HR = 0.65; 95% CI = 0.51–0.82; p = 0.00029, < 0.001, Figure 3A) and relapse-free survival (RFS) in a cohort of 4,929 BC patients (HR = 0.61; 95% CI = 0.55–0.69; p < 1E-16, < 0.001, Figure 3B).